Skip to content

Caroline Dealy

Caroline Dealy - imaged headshot 1

DeMay Bio

2019

Affiliations

University of Connecticut

Technologies

Therapeutic

Indication

Autoimmune & Inflammation

Drug Discovery

Oncology

Personalized Medicine

Executive Summary

View/Download

Additional Information

Women Owned

DeMay Bio is developing a biologic drug for Rheumatoid Arthritis that leverages a natural human protein to target a novel, but validated, disease mechanism directly in the joints. The new drug is an adjunct therapy, to be used alongside a patient’s immunosuppressant regimen,  to achieve better disease control, and to reduce disabling joint pain, tissue damage and mobility loss.

Newsletter Signup

Corporate Supporters

ABCT is a Program of

An intiative of